BEAT BioTherapeutics Corp. (BEATBio) is developing BB-R12, a novel biological therapy with the potential to revolutionize the treatment of heart failure. Approximately 6 million Americans are living with heart failure today. New therapies to address this “epidemic” are urgently needed to decrease patient mortality, improve patient quality of life and address the burgeoning cost of care.
BB-R12 therapy is based on the fundamental discovery that dATP is a superior fuel for cardiac muscle contraction than is ATP. In cardiac muscle cells – dATP synthesis is driven by a well characterized enzyme, ribonucleotide reductase. BB-R12 (delivering an optimized form of ribonucleotide reductase) increases intracellular dATP making it available to promote greatly improved myofilament cross-bridge formation resulting in improved cell contraction, tissue and organ contraction, improved muscle relaxation and significantly improved cardiac performance. BB-R12 is being developed to treat heart failure by increasing cardiac performance and this therapy has also demonstrated significant potential to prevent or delay the onset of heart failure. BB-R12 has shown efficacy and safety in a multiple animal models, including a mini-pig disease model.
BEATBio holds worldwide rights to this technology and used a recently raised $2.9MM seed financing to successfully complete the initial stages of pre-clinical development and manufacturing scale up. We have assembled a strong team of advisers and contractors that allowed us to achieve significant milestones in our first nine months. We are now raising a Series A to complete IND enabling studies and commence Phase I human trials.
BEATBio’s founders, from the University of Washington, are recognized experts in cardiovascular biology, muscle physiology and bioengineering and have received nearly $50MM of NIH funding to develop the technology.
Accomplishments’ to date:
- Demonstrated that BB-R12 dramatically restores ejection fraction and overall cardiac performance in animal models of heart failure and improves contraction and relaxation to healthy and depressed muscle cells following injury with no safety issues identified to date
- Developed and manufactured a humanized construct and scaled up manufacturing using a system licensed from the NIH – a baculo – at Florida Biologix and repeated/confirmed rodent work
- Completing a successful POC study with the test article in a mini pig model at our CRO – NAMSA
Thank you for your interest in BEATBio and we look forward to talking with you.